Conversion Ability of Immunotherapy in Hepatocellular Carcinoma: Insights from the International Converse Study.

ABSTRACT:

Introduction

The potential for curative conversion with immunotherapy-based systemic treatment used with noncurative intent in patients with hepatocellular carcinoma (HCC) remains debated. This study aimed to provide a reliable epidemiological snapshot of response patterns to atezolizumab plus bevacizumab (AB) therapy, with a focus on curative conversion rates.

Methods

Patients with HCC undergoing first-line noncurative AB or lenvatinib (LENV, used as reference) from 2019 to 2023 were included, using centre-level aggregate data from a broad international consortium. The primary endpoint was the curative conversion rate, differentiating potential conversion (PC) - when objective response (OR) resulted in a consistent decrease in tumour burden and alpha-fetoprotein levels - fr

SUBMITTER: Vitale A 

PROVIDER: S-EPMC12503878 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature